FIELD: medicine.
SUBSTANCE: invention relates to experimental medicine and concerns researching compounds with psychotropic and act-protective properties at the preclinical observation stage. Method comprises forming control and experimental groups of animals (rats), administration of the preparation and testing of animals. At that, method also comprises determining the values of cognitive abilities, research activity, motivational-energy parameters and anxiety level for each animal of both groups. In compliance with that, the animals are divided into three types, determining the possibility of their efficient use for testing preparations of one or another action. First type includes animals with the initial cognitive index from 0 to 45 %, with the integral research activity index in the range of 60 to 100 %. Second type includes animals with the initial cognitive index from 45 to 60 %, with the integral research activity index in the range of 45-60 %. Third type includes animals with the initial cognitive index from 60 to 100 %, with the integral research activity index in the range from 0 to 45 %. Animals of the first type is used for testing psychotropic preparations. Animals of the second type is used for studying psychotropic preparations, as well as act-protective preparations. Animals of the third type is preferably used for studying act-protective preparations. Testing with preliminary selection of laboratory animals is performed on the same tool, made with the possibility of arbitrary change of its architecture, in the form of a raised cross-shaped labyrinth, open field or universal problem chamber. Qualitative and quantitative of congenital or acquired behaviour are registered.
EFFECT: method provides reliable testing and opens additional possibility to detect biological properties of known preparations, as well as new compounds with potential psychotropic and act-protective properties.
4 cl, 6 dwg, 2 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR NONINVASIVE TESTING OF THE DEVELOPMENT OF MODEL PATHOLOGY OF THE MUSCULOSKELETAL SYSTEM IN LABORATORY ANIMALS | 2021 |
|
RU2771256C1 |
NEW N-ARYLSULPHAMIDE DERIVATIVE OF O-BENZOILAMINE-BENZOIC ACID WITH ANXIOLYTIC, ACTOPROTECTIVE AND ANTIDEPRESSANT ACTIVITY | 2016 |
|
RU2643356C2 |
EVALUATION METHOD FOR ANXIOGENIC ACTIVITY OF POTENTIAL MEDICINAL PREPARATIONS | 2006 |
|
RU2342712C2 |
METHOD OF CORRECTION OF INDICATORS OF MOTIVATION-ENERGY AND COGNITIVE SPHERES IN LABORATORY ANIMALS | 2015 |
|
RU2626680C2 |
QUINAZOLIN-4(3H)-ONE DIMETHOXYBENZYLSULFO DERIVATIVE WITH ANALGESIC, ANTIPARKINSONIAN, ANXIOLYTIC, PSYCHOSTIMULATING ACTIVITY | 2021 |
|
RU2758333C1 |
METHOD OF ASSESSING COGNITIVE FUNCTIONS AND MEMORY IMPAIRMENT IN LABORATORY ANIMALS | 2022 |
|
RU2808376C1 |
ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
METHOD FOR DETECTING PSYCHOTROPIC ACTIVITY OF DRUG AND DRUG-FREE SUBSTANCES | 2012 |
|
RU2506649C1 |
METHOD OF ASSESSING INDIVIDUAL STRESS RESISTANCE OF SMALL LABORATORY ANIMALS | 2022 |
|
RU2802762C1 |
9-[2-(4-ISOPROPYLPHENOXY)ETHYL]ADENINE POSSESSING ANTIDEPRESSANT AND STRESS-RELIEVING ACTION | 2013 |
|
RU2529817C1 |
Authors
Dates
2016-11-10—Published
2015-10-06—Filed